カテゴリ： GlobalData, 企業調査, 南アフリカ

Aspen Pharmacare Holdings Ltd (APN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12366
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：南アフリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company focuses on thrombosis, anesthetics and high potency and cytotoxics therapeutic categories. It also manufactures infant nutritionals and consumer healthcare products in selected territories. Its manufacturing capabilities cover a range of product-types including oral solid dose, semi-solids, liquids, steriles, biological, active pharmaceutical ingredients (APIs) and infant nutritionals. The company has presence in Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Ltd (APN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 28
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 31
Partnerships 33
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33
AstraZeneca Enters into Co-Marketing Agreement with Aspen 34
ANI Pharma Enters into Distribution Agreement with Aspen 35
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36
Navamedic Amends Distribution Agreement With Aspen Pharma 37
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38
Licensing Agreements 39
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39
Aspen Pharma Enters into Licensing Agreement with Starpharma 40
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44
Equity Offering 45
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45
Asset Transactions 47
Endo International Acquires Portfolio of Branded and Generic Products 47
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 52
Acquisition 53
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 54
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 55
Aspen Pharmacare Holdings Ltd – Key Competitors 56
Aspen Pharmacare Holdings Ltd – Key Employees 57
Aspen Pharmacare Holdings Ltd – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 61
Recent Developments 62
Financial Announcements 62
Mar 08, 2018: Aspen delivers double digit revenue and earnings growth 62
Sep 14, 2017: Aspen increases revenue by 16% to R41.2 billion 65
Mar 09, 2017: Aspen: Unaudited interim financial results for the six months ended 31 December 2016 68
Legal and Regulatory 71
Jun 13, 2017: Aspen: South African Competition Commission Announcement 71
May 15, 2017: Aspen: Opening of European Commission proceedings 72
Apr 24, 2017: Aspen’s response to the reported Competition Commission investigation 73
Government and Public Interest 74
May 29, 2017: Aspen Cleared of Alleged Anti-competitive Behavior by DA 74
May 15, 2017: Antitrust: Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines 75
Other Significant Developments 77
Oct 26, 2018: Aspen’s participation in the 2018 Investment Conference 77
Mar 01, 2017: Aspen – Trading Statement 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 28
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 31
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33
AstraZeneca Enters into Co-Marketing Agreement with Aspen 34
ANI Pharma Enters into Distribution Agreement with Aspen 35
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36
Navamedic Amends Distribution Agreement With Aspen Pharma 37
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39
Aspen Pharma Enters into Licensing Agreement with Starpharma 40
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45
Endo International Acquires Portfolio of Branded and Generic Products 47
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 52
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 54
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 55
Aspen Pharmacare Holdings Ltd, Key Competitors 56
Aspen Pharmacare Holdings Ltd, Key Employees 57
Aspen Pharmacare Holdings Ltd, Other Locations 58
Aspen Pharmacare Holdings Ltd, Subsidiaries 58
Aspen Pharmacare Holdings Ltd, Joint Venture 61

List of Figures
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Aspen Pharmacare Holdings Ltd (APN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • VTB Bank：戦略・SWOT・企業財務分析
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Cereno Scientific AB (CRNO TO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Cereno Scientific AB (Cereno Scientific) is a developer of preventive drugs that normalize the body's own defense system against blood clots. The company develops drugs in the therapeutic area of thrombosis-related cardiovascular diseases. Its lead product candidate CS1 is being developed fo …
  • Aluminium Bahrain BSC (ALBH)：企業の財務・戦略的SWOT分析
    Aluminium Bahrain BSC (ALBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Alleghany Corporation：企業の戦略・SWOT・財務情報
    Alleghany Corporation - Strategy, SWOT and Corporate Finance Report Summary Alleghany Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tri-State Generation and Transmission Association Inc：企業の戦略的SWOT分析
    Tri-State Generation and Transmission Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key com …
  • Liberty Holdings Ltd：戦略・SWOT・企業財務分析
    Liberty Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Liberty Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Samart Corporation Public Co Ltd (SAMART)：企業の財務・戦略的SWOT分析
    Samart Corporation Public Co Ltd (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Vaisala oyj (VAIAS)：企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • John Keells Hotels Plc
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Craneware plc (CRW)：企業の財務・戦略的SWOT分析
    Summary Craneware plc (Craneware) is a healthcare technology company that provides revenue integrity solutions. The company provides patient engagement, charge capture and pricing; coding integrity, and revenue recovery and retention products, chargemaster tool kit, online reference tool kit, physic …
  • Entergy Corporation (ETR)-エネルギー分野：企業M&A・提携分析
    Summary Entergy Corporation (Entergy) is an integrated energy company that generates, transmits, distributes and sells electricity. The company generates electricity from various sources including natural gas, nuclear, coal, hydroelectric and oil based power plants. Entergy also operates a natural g …
  • Mesoblast Ltd (MSB)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft ve …
  • Banco Santander SA：戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PG&E Corp (PCG)：電力：M&Aディール及び事業提携情報
    Summary PG&E Corp (PG&E) is an energy-based holding company. It has interests in Pacific Gas and Electric Company. PG&E generates, transmits, and distributes electricity. The company produces electricity using nuclear, hydro, fuel cell, solar, and fossil fuel sources. Through CPUC-approved procureme …
  • Hindustan Petroleum Corp Ltd (HINDPETRO)：石油・ガス：M&Aディール及び事業提携情報
    Summary Hindustan Petroleum Corp Ltd (HPCL) is a downstream oil and gas company that carries out refining, transportation and marketing of petroleum products. It is also has operations in upstream segment of oil and gas industry. HPCL carries out exploration and production in India; and Australia. T …
  • Fibrocell Science Inc (FCSC)：医療機器：M&Aディール及び事業提携情報
    Summary Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic …
  • The Chugoku Electric Power Co., Inc.：企業の戦略・SWOT・財務情報
    The Chugoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary The Chugoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • El Paso Electric Co (EE)：企業の財務・戦略的SWOT分析
    El Paso Electric Co (EE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Strauss Group Ltd.：企業の戦略・SWOT・財務情報
    Strauss Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Strauss Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Komeri Co Ltd：企業の戦略・SWOT・財務分析
    Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆